Sean Madsen
About Sean Madsen
Sean Madsen is a Principal Scientist at Bristol Myers Squibb in Seattle, Washington, with extensive experience in cell therapy analytical development and a strong background in chemical and biomolecular engineering.
Current Role at Bristol Myers Squibb
Sean Madsen currently holds the position of Principal Scientist at Bristol Myers Squibb in Seattle, Washington. His work focuses on advancing scientific research and development within the company, particularly in the realm of cell therapy and analytical development. His expertise in the field plays a crucial role in driving innovative solutions for drug development and therapeutic applications.
Previous Experience at Bristol Myers Squibb
Prior to his current role, Sean Madsen served as a Senior Scientist in Cell Therapy Analytical Development at Bristol Myers Squibb. From 2020 to 2022, he worked in the Greater Seattle Area, contributing significantly to the development of analytical methods for evaluating cell therapy products. His work involved collaboration across various functions to enhance quality control and characterization of autologous cell therapies.
Academic Background at Tulane University
Sean Madsen completed his Doctor of Philosophy (PhD) in Chemical and Biomolecular Engineering at Tulane University. Over the course of six years, from 2013 to 2019, he conducted research focused on molecular, biochemical, and cell-based assays. Additionally, he earned a Master of Science (MS) in Biomedical Sciences, General from the same institution, further honing his expertise in the field.
Undergraduate Studies at University of Maryland
Sean Madsen earned his Bachelor of Science (BS) in Chemical and Biomolecular Engineering from the University of Maryland. During his four-year undergraduate program, he built a solid foundation in the principles of chemical engineering, which later supported his advanced studies and professional work in the field.
Nine Years of Research Experience
Sean Madsen has accumulated nine years of research experience focused on molecular, biochemical, and cell-based assays. His work has been pivotal in assessing mesenchymal stem cell (MSC) and chimeric antigen receptor (CAR) T cell therapies. This extensive research background has equipped him with the skills necessary to develop innovative methods for evaluating and improving therapeutic products.